Innate Pharma S.A.
IPH.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €5 | €8 | €12 | €21 |
| % Growth | -37.5% | -37% | -42.4% | – |
| Cost of Goods Sold | €21 | €23 | €29 | €25 |
| Gross Profit | -€16 | -€15 | -€17 | -€3 |
| % Margin | -322.2% | -194.5% | -135.5% | -14.6% |
| R&D Expenses | €21 | €23 | €28 | €24 |
| G&A Expenses | €10 | €11 | €9 | €9 |
| SG&A Expenses | €10 | €9 | €10 | €9 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€21 | €0 | -€28 | -€23 |
| Operating Expenses | €10 | €32 | €10 | €9 |
| Operating Income | -€25 | -€25 | -€26 | -€12 |
| % Margin | -523.2% | -324.9% | -213.1% | -57.2% |
| Other Income/Exp. Net | €4 | €1 | €2 | €3 |
| Pre-Tax Income | -€21 | -€25 | -€25 | -€9 |
| Tax Expense | €0 | -€3 | €0 | €0 |
| Net Income | -€21 | -€25 | -€25 | -€9 |
| % Margin | -439.2% | -317.7% | -200.6% | -43.3% |
| EPS | -0.25 | -0.3 | -0.31 | -0.12 |
| % Growth | 16.7% | 3.2% | -158.3% | – |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.11 |
| Weighted Avg Shares Out | 85 | 61 | 61 | 61 |
| Weighted Avg Shares Out Dil | 87 | 81 | 81 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | €1 | €5 | €3 | €12 |
| Interest Expense | €0 | €4 | €1 | €3 |
| Depreciation & Amortization | €0 | €1 | €1 | €2 |
| EBITDA | -€25 | -€23 | -€26 | -€10 |
| % Margin | -515.7% | -296.5% | -207.1% | -48.5% |